このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

RISS Versus Lower Thoracic ESP Block for Analgesia After Laparoscopic Abdominal Surgery: A Randomized Trial

2026年5月13日 更新者:Emad Lotfy Mohammed Ahmed、Misr University for Science and Technology

Analgesic Efficacy of Ultrasound-Guided Rhomboid Intercostal and Subserratus (RISS) Block Versus Lower Thoracic Erector Spinae Plane Block (ESPB) After Abdominal Laparoscopic Surgery

The goal of this clinical trial is to investigate the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block versus lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery. The main questions it aims to answer are:

Does ultrasound-guided Romboid Intercostal and Subserratus (RISS) block is effective as the lower thoracic Erector Spinae Plane (ESP) block for intra and postoperative analgesia after laparoscopic abdominal surgery for the first 24 hours? What complications do participants have when doing these interventions?

Researchers will compare the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block with the lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery.

Participants will:

Start general anesthesia and be given either block according to the randomization chart.

The blood pressure and heart rate will be measured at intervals to determine if the participants need extra intraoperative analgesics.

Numerical Rating Scale (NRS) will be used postoperatively to test pain severity.

Rescue morphine analgesia will be measured and compared in both groups.

Any complications will be reported.

Patient and surgeon satisfaction will be measured.

調査の概要

詳細な説明

The aim of this study is to investigate the analgesic efficacy of ultrasound-guided Romboid Intercostal and Subserratus (RISS) block versus lower thoracic Erector Spinae Plane (ESP) block after laparoscopic abdominal surgery.

Hypothesis

This study hypothesize that both RISS and ESP blocks relieve somatic pain equally, but ESP block relieves visceral pain better than RISS block, thereby reducing opioid consumption and improving patient satisfaction.

Methodology using:

I. Study design

Double-blinded randomized clinical trial study.

II. Study setting and location The study will be conducted at the operative theater of Souad Kafafi University Hospital (SKUH), Misr University for Science and Technology (MUST).

III. Study population:

Patients aged from 18 to 60 years old scheduled for laparoscopic abdominal surgery will be randomized in a 1:1 ratio after induction of general anesthesia, either:

Group A: Receiving ultrasound-guided RISS block. A solution composed of 20 ml mixed xylocaine 1% + 0.25% bupivacaine + 4 mg dexamethasone on each side.

Group B: Receiving ultrasound-guided lower thoracic ESP block (T8-T9) A solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.

The infiltrative local anesthesia will be administered via a 22-gauge, 80-mm Echogenic block needle.

Postoperative analgesia:

The participants in both groups will receive analgesia in accordance with the following protocol:

  • Pain will be assessed using a Numerical Rating Scale (NRS) 0-10.

    1. Mild pain (NRS 1-3) will be treated with 1 g paracetamol IV every six hours (maximum 4 g/day).
    2. Moderate pain (NRS 4-6) will receive the same paracetamol regimen plus ketorolac 30 mg IV every eight hours (maximum 120 mg/day).
    3. Severe pain (NRS 7-10) will receive the above plus 0.1 mg/kg IV morphine when indicated.

      Study outcomes:

      Primary Outcome Measure:

  • Efficacy of postoperative analgesia for first 24 hours.

Secondary Outcome Measures:

  • Total morphine equivalent consumption (mg) in 24 h.
  • Surgeon satisfaction (ability to perform active movements, 1-5 scale).
  • Patient satisfaction (1-5 scale).
  • Onset time of analgesia (min).
  • Duration of postoperative analgesia (time to first rescue).
  • Pain intensity via NRS at 2, 6, 12, 18, and 24 h.
  • Intraoperative vital signs (HR, NIBP).
  • Possible complications (pneumothorax, LAST, and vascular puncture) intra- and post-operatively.

Sample size calculation The sample size calculation was performed using G. power 3.1.9.2 (Universität Kiel, Germany). The sample size was calculated according to the total morphine dose in 24hr (4.21 in RISS vs. 4.65 in ESP) according to previous studies (9, 10). Based on the following considerations: 0.05 α error and 80% power of the study. Four cases were added to overcome dropout. Therefore, 70 patients will be allocated.

Statistical Analysis Statistical analysis will be done by SPSS v26 (IBM Inc., Chicago, IL, USA). Shapiro-Wilks test and histograms will be used to evaluate the normality of the distribution of data. Quantitative parametric variables will be presented as mean and standard deviation (SD) and compared between the two groups utilizing unpaired Student's t- test. Quantitative non-parametric data will be presented as median and interquartile range (IQR) and will be analyzed by Mann Whitney-test. Qualitative variables will be presented as frequency and percentage (%) and will be analyzed utilizing the Chi-square test or Fisher's exact test when appropriate. A two tailed P value < 0.05 will be considered statistically significant.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Mohamed M Ahmed, Resident
  • 電話番号:0201147888382
  • メール:Manmoh980@gmail.com

研究場所

    • Giza Governorate
      • Giza、Giza Governorate、エジプト、15525
        • Souad Kafafi University Hospital (SKUH), Faculty of Medicine, MUST

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Patients scheduled for laparoscopic abdominal surgery (e.g., cholecystectomy, colectomy, sleeve gastrectomy, hernia repair, appendectomy).
  • Age from 18 - 60 years old.
  • Both sexes.
  • American Society of Anesthesiology (ASA) classification I, II. (i.e., ASA I: a normal healthy patient; ASA II: patients with mild controlled systemic disease.

Exclusion Criteria:

  • Patients who refuse the research consent.
  • Allergy to local anesthetic drugs.
  • Cardiac arrhythmia.
  • Bleeding tendency (including pre-existing blood disease and patients on full anticoagulant therapy).
  • Morbid obese patients (BMI>35 kg/m2)
  • Vascular compromise of lower extremity (e.g., Burger disease, Raynaud's disease).
  • Connective tissue disease (e.g., Scleroderma).
  • Suspected malignancy or intra-abdominal infection.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group A (n=35): Ultrasound-guided RISS block.
The patient will be positioned in the lateral decubitus with the ipsilateral arm abducted to move the scapula laterally and open the intercostal and subscapular spaces. A high-frequency linear probe (10-14 MHz) will be applied 1-2 cm medial to the medial scapular border in an oblique-sagittal plane at the T5-T6 level. Using an in-plane approach, a 22 G, 80 mm block needle will be advanced from superomedial to inferolateral (cephalocaudal) until the tip lies between RM and ICM. After negative aspiration and hydrodissection with 1-2 ml saline, 10 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time observation of spread deep to RM. The probe will then be slid caudally and laterally to the T8-T9 level to visualize the fascial plane at the mid-axillary line between the serratus anterior (SA) muscle and the external intercostal muscle to inject the other 10 ml of local anesthetic.
The patient will be positioned in the lateral decubitus with the ipsilateral arm abducted to move the scapula laterally and open the intercostal and subscapular spaces. A high-frequency linear probe (10-14 MHz) will be applied 1-2 cm medial to the medial scapular border in an oblique-sagittal plane at the T5-T6 level. Using an in-plane approach, a 22 G, 80 mm block needle will be advanced from superomedial to inferolateral (cephalocaudal) until the tip lies between RM and ICM. After negative aspiration and hydrodissection with 1-2 ml saline, 10 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time observation of spread deep to RM. The probe will then be slid caudally and laterally to the T8-T9 level to visualize the fascial plane at the mid-axillary line between the serratus anterior (SA) muscle and the external intercostal muscle to inject the other 10 ml of local anesthetic.
アクティブコンパレータ:Group B (n=35): Receiving ultrasound-guided lower thoracic ESP block
The patient will be positioned laterally. A linear probe will be placed 3 cm lateral to the posterior midline at the T8-T9 level to identify the transverse process (TP) and erector spinae muscle (ESM). A 22 G, 80 mm Echogenic block needle will be advanced in-plane from cranial to caudal until the tip rests deep to ESM but superficial to the TP. After negative aspiration, 20 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time ultrasound confirmation of longitudinal spread cranially and caudally along the fascial plane. The block will be performed bilaterally following the same stepsA solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.
The patient will be positioned laterally. A linear probe will be placed 3 cm lateral to the posterior midline at the T8-T9 level to identify the transverse process (TP) and erector spinae muscle (ESM). A 22 G, 80 mm Echogenic block needle will be advanced in-plane from cranial to caudal until the tip rests deep to ESM but superficial to the TP. After negative aspiration, 20 ml of the prepared solution (1% lidocaine + 0.25% bupivacaine + 4 mg dexamethasone) will be injected in 5 ml aliquots, with real-time ultrasound confirmation of longitudinal spread cranially and caudally along the fascial plane. The block will be performed bilaterally following the same stepsA solution composed of 20 ml mixed xylocaine 1% + 0.25 % bupivacaine + 4 mg dexamethasone on each side.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Postoperative analgesia
時間枠:from 0 to 24 hours postoperative

Pain will be assessed using a Numerical Rating Scale (NRS) (0-10 scale).

Will be measured by NRS at 0, 6, 12, 18, and 24 hours postoperative

  1. Mild pain (NRS 1-3) will be treated with 1 g paracetamol IV every six hours (maximum 4 g/day).
  2. Moderate pain (NRS 4-6) will receive the same paracetamol regimen plus ketorolac 30 mg IV every eight hours (maximum 120 mg/day).
  3. Severe pain (NRS 7-10) will receive the above plus 0.1 mg/kg IV morphine when indicated.
from 0 to 24 hours postoperative

二次結果の測定

結果測定
メジャーの説明
時間枠
Total morphine consumption (mg) in 24 h.
時間枠:from 0 to 24 hours postoperative
Doses of morphine given intravenous postoperatively according to severity of pain (NRS > 6) during the first 24 hours postoperatively
from 0 to 24 hours postoperative
Intra-operative vital signs (HR)
時間枠:Before induction of anesthesia till the end of surgery
Measuring the patient's heart rate (HR) before induction of anesthesia and every 15 minutes during surgery.
Before induction of anesthesia till the end of surgery
• Intra-operative vital signs: Mean Blood Pressure (MBP)
時間枠:Before induction of anesthesia till the end of surgery
Measuring the patient's Mean Blood Pressure (MBP) before induction of anesthesia and every 15 minutes during surgery.
Before induction of anesthesia till the end of surgery
Possible complications
時間枠:Intra- and post-operatively for 24 hours.
pneumothorax, LAST, vascular puncture
Intra- and post-operatively for 24 hours.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディチェア:Manar M ElKholy, Profesor、Prof. of Anesth, Kasr Alainy hospital, Faculty of Medicine, Cairo University
  • スタディディレクター:Mohamed Abdelaziz Taha, Assist. Prof.、Assist. Prof. of Anesth, Souad Kafafi University hospital, Faculty of Medicine, MUST
  • スタディディレクター:Ahmed SK Elkhodary, Lecturer、Lecturer of surgery at Souad Kafafi University hospital, Faculty of Medicine, MUST

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年5月20日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2026年4月28日

QC基準を満たした最初の提出物

2026年5月13日

最初の投稿 (実際)

2026年5月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月18日

QC基準を満たした最後の更新が送信されました

2026年5月13日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2025/0124

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Demographic Information: Age, sex, race, and other relevant demographic details.

Baseline Characteristics: Health status, medical history, and any pre-existing conditions prior to the trial.

Treatment Assignment: Information on the intervention or treatment each participant received.

Outcome Measures: Data on primary and secondary outcomes as defined in the trial protocol.

Adverse Events: Reports of any side effects or adverse events experienced by participants during the trial.

Follow-up Data: Information collected during follow-up periods, including long-term outcomes

IPD 共有時間枠

may 2026 to December 2026

IPD 共有アクセス基準

Researchers:

Who: Academic researchers, industry scientists, and regulatory agencies. What: Full IPD, including demographic data, treatment assignments, and outcome measures.

How: Through data sharing platforms or repositories after submitting a research proposal and obtaining necessary approvals.

Regulatory Authorities:

Who: Agencies like the FDA or EMA. What: Full IPD and supporting documentation for oversight and review. How: Direct access during the review process of clinical trial applications.

Data Sharing Initiatives:

Who: Collaborating institutions and consortia. What: Aggregated or anonymized IPD for meta-analyses or systematic reviews. How: Via established partnerships and shared databases.

Public and Patient Advocacy Groups:

Who: Organizations seeking to promote transparency. What: Summary data and aggregated results, but not individual-level data. How: Through publicly available reports or dashboards.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する